Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Ovarian Neoplasms

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 191 articles:
HTML format

Single Articles

    May 2021
  1. PIROLLI R, de Alencar VTL, Estati FL, Ribeiro ARG, et al
    Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.
    BMC Cancer. 2021;21:525.
    PubMed     Abstract available

  2. LAPKE N, Chen CH, Chang TC, Chao A, et al
    Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    BMC Cancer. 2021;21:499.
    PubMed     Abstract available

  3. SHIN W, Park SY, Kang S, Lim MC, et al
    How to manage synchronous endometrial and ovarian cancer patients?
    BMC Cancer. 2021;21:489.
    PubMed     Abstract available

    April 2021
  4. XUE B, Li S, Jin X, Liu L, et al
    Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
    BMC Cancer. 2021;21:452.
    PubMed     Abstract available

  5. LI S, Yang T, Xiang Y, Li X, et al
    Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.
    BMC Cancer. 2021;21:383.
    PubMed     Abstract available

  6. HAWARDEN A, Russell B, Gee ME, Skayali F, et al
    Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
    BMC Cancer. 2021;21:378.
    PubMed     Abstract available

    March 2021
  7. ZHU C, Zhu J, Qian L, Liu H, et al
    Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    BMC Cancer. 2021;21:322.
    PubMed     Abstract available

  8. TOPNO R, Singh I, Kumar M, Agarwal P, et al
    Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    BMC Cancer. 2021;21:220.
    PubMed     Abstract available

    February 2021
  9. GUO J, Satoh K, Tabata S, Mori M, et al
    Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
    BMC Cancer. 2021;21:174.
    PubMed     Abstract available

  10. ZHANG H, Zhang K, Xu Z, Chen Z, et al
    MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation.
    BMC Cancer. 2021;21:163.
    PubMed     Abstract available

    January 2021
  11. LI J, Yue H, Yu H, Lu X, et al
    Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
    BMC Cancer. 2021;21:67.
    PubMed     Abstract available

  12. YAN S, Fang J, Chen Y, Xie Y, et al
    Correction to: Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
    BMC Cancer. 2021;21:55.

  13. GRIMES MM, Kenney SR, Dominguez DR, Brayer KJ, et al
    The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo.
    BMC Cancer. 2021;21:40.
    PubMed     Abstract available

  14. KAYAHASHI K, Mizumoto Y, Matsuoka A, Obata T, et al
    Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    BMC Cancer. 2021;21:32.
    PubMed     Abstract available

    December 2020
  15. KIM SI, Hwang WY, Lee M, Kim HS, et al
    Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles.
    BMC Cancer. 2020;20:1199.
    PubMed     Abstract available

  16. YAN S, Fang J, Chen Y, Xie Y, et al
    Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
    BMC Cancer. 2020;20:1205.
    PubMed     Abstract available

    November 2020
  17. TSUTSUMI M, Miura H, Inagaki H, Shinkai Y, et al
    An aggressive systemic mastocytosis preceded by ovarian dysgerminoma.
    BMC Cancer. 2020;20:1162.
    PubMed     Abstract available

    October 2020
  18. LI M, Cheng X, Rong R, Gao Y, et al
    High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    BMC Cancer. 2020;20:1032.
    PubMed     Abstract available

  19. SONG L, Tang Z, Peng C, Yang Y, et al
    Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
    BMC Cancer. 2020;20:1020.
    PubMed     Abstract available

  20. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women.
    BMC Cancer. 2020;20:1009.
    PubMed     Abstract available

  21. FOGG KC, Miller AE, Li Y, Flanigan W, et al
    Ovarian cancer cells direct monocyte differentiation through a non-canonical pathway.
    BMC Cancer. 2020;20:1008.
    PubMed     Abstract available

  22. STOCKLEY J, Akhand R, Kennedy A, Nyberg C, et al
    Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours.
    BMC Cancer. 2020;20:1000.
    PubMed     Abstract available

  23. HOOVER AA, Hufnagel DH, Harris W, Bullock K, et al
    Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.
    BMC Cancer. 2020;20:970.
    PubMed     Abstract available

  24. ESCALONA RM, Bilandzic M, Western P, Kadife E, et al
    TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
    BMC Cancer. 2020;20:960.
    PubMed     Abstract available

    September 2020
  25. HU J, Jiao X, Zhu L, Guo H, et al
    Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
    BMC Cancer. 2020;20:938.
    PubMed     Abstract available

  26. ZHANG D, Chen X, Xia H, Wang L, et al
    Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.
    BMC Cancer. 2020;20:845.
    PubMed     Abstract available

    August 2020
  27. LI N, Gou J, Li L, Ming X, et al
    Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: a retrospective analysis of 448 cases.
    BMC Cancer. 2020;20:769.
    PubMed     Abstract available

  28. EL ANSARI FZ, Jouali F, Marchoudi N, Bennani MM, et al
    Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    BMC Cancer. 2020;20:747.
    PubMed     Abstract available

    July 2020
  29. GOBEL A, Zinna VM, Dell'Endice S, Jaschke N, et al
    Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
    BMC Cancer. 2020;20:703.
    PubMed     Abstract available

  30. LI T, Wang J
    Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    BMC Cancer. 2020;20:678.
    PubMed     Abstract available

  31. FANG C, Zhang Y, Zhao L, Chen X, et al
    The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
    BMC Cancer. 2020;20:654.
    PubMed     Abstract available

    June 2020
  32. ITO M, Kodaira T, Koide Y, Okuda T, et al
    Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study.
    BMC Cancer. 2020;20:540.
    PubMed     Abstract available

    May 2020
  33. TSUYOSHI H, Orisaka M, Fujita Y, Asare-Werehene M, et al
    Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
    BMC Cancer. 2020;20:467.
    PubMed     Abstract available

  34. CHOI J, Topouza DG, Tarnouskaya A, Nesdoly S, et al
    Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
    BMC Cancer. 2020;20:413.
    PubMed     Abstract available

  35. VAN DER MERWE NC, Oosthuizen J, Theron M, Chong G, et al
    The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
    BMC Cancer. 2020;20:391.
    PubMed     Abstract available

  36. PARK SJ, Shim SH, Ji YI, Kwon SH, et al
    Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    BMC Cancer. 2020;20:385.
    PubMed     Abstract available

  37. MALGUNDKAR SH, Burney I, Al Moundhri M, Al Kalbani M, et al
    FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and beta-catenin activity in ovarian cancer.
    BMC Cancer. 2020;20:374.
    PubMed     Abstract available

    April 2020
  38. TANABE Y, Shiraishi S, Hashimoto K, Ikeda K, et al
    Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
    BMC Cancer. 2020;20:325.
    PubMed     Abstract available

  39. LIU D, Cai J, Gao A, Wang Z, et al
    Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival.
    BMC Cancer. 2020;20:320.
    PubMed     Abstract available

  40. DASARI VR, Carey DJ, Gogoi R
    Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    BMC Cancer. 2020;20:273.
    PubMed     Abstract available

    March 2020
  41. SHI J, Zhou Z, Di W, Li N, et al
    Retraction Note: Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
    BMC Cancer. 2020;20:236.
    PubMed     Abstract available

  42. LI N, Gou JH, Xiong J, You JJ, et al
    HOXB4 promotes the malignant progression of ovarian cancer via DHDDS.
    BMC Cancer. 2020;20:222.
    PubMed     Abstract available

  43. SUN C, Guo E, Zhou B, Shan W, et al
    Correction to: A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
    BMC Cancer. 2020;20:210.
    PubMed     Abstract available

  44. EOH KJ, Kim HM, Lee JY, Kim S, et al
    Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    BMC Cancer. 2020;20:204.
    PubMed     Abstract available

  45. PRZYBYTKOWSKI E, Davis T, Hosny A, Eismann J, et al
    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    BMC Cancer. 2020;20:197.
    PubMed     Abstract available

  46. ONWUKA JU, Okekunle AP, Olutola OM, Akpa OM, et al
    Lipid profile and risk of ovarian tumours: a meta-analysis.
    BMC Cancer. 2020;20:200.
    PubMed     Abstract available

  47. LEE YJ, Kim HS, Rim JH, Lee JY, et al
    Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
    BMC Cancer. 2020;20:185.
    PubMed     Abstract available

    February 2020
  48. HE Y, Li T, Liu J, Ou Q, et al
    Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer.
    BMC Cancer. 2020;20:116.
    PubMed     Abstract available

    December 2019
  49. YUE H, Wang J, Chen R, Hou X, et al
    Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.
    BMC Cancer. 2019;19:1266.
    PubMed     Abstract available

  50. KAJIYAMA H, Suzuki S, Yoshikawa N, Kawai M, et al
    Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer ~propensity score- matched analysis~.
    BMC Cancer. 2019;19:1235.
    PubMed     Abstract available

  51. DE SABANDO AR, Lafuente EU, Garcia-Amigot F, Sanchez AA, et al
    Correction to: Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    BMC Cancer. 2019;19:1227.
    PubMed     Abstract available

  52. HAN GH, Chay DB, Nam S, Cho H, et al
    Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer.
    BMC Cancer. 2019;19:1202.
    PubMed     Abstract available

  53. DA COSTA AABA, Dos Santos ES, Cotrim DP, Pandolfi NC, et al
    Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.
    BMC Cancer. 2019;19:1194.
    PubMed     Abstract available

    November 2019
  54. YE S, Hao X, Zhou T, Wu M, et al
    Correction to: Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.
    BMC Cancer. 2019;19:1164.
    PubMed     Abstract available

  55. RUIZ DE SABANDO A, Urrutia Lafuente E, Garcia-Amigot F, Alonso Sanchez A, et al
    Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    BMC Cancer. 2019;19:1145.
    PubMed     Abstract available

  56. SHI J, Huo R, Li N, Li H, et al
    CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    BMC Cancer. 2019;19:1140.
    PubMed     Abstract available

  57. MALIK MZ, Chirom K, Ali S, Ishrat R, et al
    Methodology of predicting novel key regulators in ovarian cancer network: a network theoretical approach.
    BMC Cancer. 2019;19:1129.
    PubMed     Abstract available

  58. SALLINEN H, Janhonen S, Polonen P, Niskanen H, et al
    Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.
    BMC Cancer. 2019;19:1121.
    PubMed     Abstract available

  59. XIONG S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, et al
    Expression of the luteinizing hormone receptor (LHR) in ovarian cancer.
    BMC Cancer. 2019;19:1114.
    PubMed     Abstract available

  60. LOU L, Zhou L, Wang W, Li H, et al
    Atypical ovarian carcinoid tumor with widespread skeletal metastases: a case report of multiple endocrine neoplasia type 1 in a young woman.
    BMC Cancer. 2019;19:1107.
    PubMed     Abstract available

  61. ZHANG W, Peng P, Ou X, Shen K, et al
    Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.
    BMC Cancer. 2019;19:1095.
    PubMed     Abstract available

  62. SUN C, Guo E, Zhou B, Shan W, et al
    A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
    BMC Cancer. 2019;19:1061.
    PubMed     Abstract available

  63. CODILUPI T, Taube D, Naegeli H
    CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling.
    BMC Cancer. 2019;19:1042.
    PubMed     Abstract available

  64. FUNSTON G, Van Melle M, Baun ML, Jensen H, et al
    Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines.
    BMC Cancer. 2019;19:1028.
    PubMed     Abstract available

    October 2019
  65. MATSUBAYASHI H, Higashigawa S, Kiyozumi Y, Horiuchi Y, et al
    Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome.
    BMC Cancer. 2019;19:1014.
    PubMed     Abstract available

  66. ZHANG Y, Luo G, Li M, Guo P, et al
    Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis.
    BMC Cancer. 2019;19:984.
    PubMed     Abstract available

    September 2019
  67. ENGQVIST H, Parris TZ, Kovacs A, Nemes S, et al
    Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas.
    BMC Cancer. 2019;19:928.
    PubMed     Abstract available

  68. YU X, Liang C, Zhang Y, Zhang W, et al
    Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells.
    BMC Cancer. 2019;19:878.
    PubMed     Abstract available

    August 2019
  69. AHN JI, Yoo JY, Kim TH, Kim YI, et al
    G-protein coupled receptor 64 (GPR64) acts as a tumor suppressor in endometrial cancer.
    BMC Cancer. 2019;19:810.
    PubMed     Abstract available

    July 2019
  70. SLIWA A, Kubiczak M, Szczerba A, Walkowiak G, et al
    Regulation of human chorionic gonadotropin beta subunit expression in ovarian cancer.
    BMC Cancer. 2019;19:746.
    PubMed     Abstract available

  71. WANG Y, Ren F, Song Z, Chen P, et al
    Statin use and the risk of ovarian and endometrial cancers: a meta-analysis.
    BMC Cancer. 2019;19:730.
    PubMed     Abstract available

  72. GONG W, Liu Y, Seidl C, Diamandis EP, et al
    Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
    BMC Cancer. 2019;19:696.
    PubMed     Abstract available

  73. MOHAMED NE, Hay T, Reed KR, Smalley MJ, et al
    APC2 is critical for ovarian WNT signalling control, fertility and tumour suppression.
    BMC Cancer. 2019;19:677.
    PubMed     Abstract available

  74. RAYES N, Bowen DJ, Coffin T, Nebgen D, et al
    MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
    BMC Cancer. 2019;19:648.
    PubMed     Abstract available

  75. LIU B, Huang X, Li Y, Liao W, et al
    JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
    BMC Cancer. 2019;19:645.
    PubMed     Abstract available

    June 2019
  76. PARADISO AV, Digennaro M, Patruno M, De Summa S, et al
    BRCA germline mutation test for all woman with ovarian cancer?
    BMC Cancer. 2019;19:641.
    PubMed     Abstract available

  77. DENG J, Bai X, Feng X, Ni J, et al
    Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    BMC Cancer. 2019;19:618.
    PubMed     Abstract available

  78. SOPO M, Anttila M, Hamalainen K, Kivela A, et al
    Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
    BMC Cancer. 2019;19:584.
    PubMed     Abstract available

  79. STUKAN M, Badocha M, Ratajczak K
    Development and validation of a model that includes two ultrasound parameters and the plasma D-dimer level for predicting malignancy in adnexal masses: an observational study.
    BMC Cancer. 2019;19:564.
    PubMed     Abstract available

  80. CAO WM, Zheng YB, Gao Y, Ding XW, et al
    Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
    BMC Cancer. 2019;19:551.
    PubMed     Abstract available

  81. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Abstract available

    May 2019
  82. KOJIMA M, Sone K, Oda K, Hamamoto R, et al
    The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
    BMC Cancer. 2019;19:455.
    PubMed     Abstract available

  83. VAN DE SANDE L, Willaert W, Cosyns S, De Clercq K, et al
    Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC).
    BMC Cancer. 2019;19:424.
    PubMed     Abstract available

  84. DA COSTA AABA, do Canto LM, Larsen SJ, Ribeiro ARG, et al
    Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    BMC Cancer. 2019;19:422.
    PubMed     Abstract available

    April 2019
  85. MATTE I, Garde-Granger P, Bessette P, Piche A, et al
    Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    BMC Cancer. 2019;19:406.
    PubMed     Abstract available

  86. ZAKRZEWSKI F, Gieldon L, Rump A, Seifert M, et al
    Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    BMC Cancer. 2019;19:396.
    PubMed     Abstract available

  87. ARFI A, Hequet D, Bataillon G, Tran-Perennou C, et al
    HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports.
    BMC Cancer. 2019;19:375.
    PubMed     Abstract available

  88. CHUNG YS, Park SY, Lee JY, Park JY, et al
    Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
    BMC Cancer. 2019;19:341.
    PubMed     Abstract available

  89. MIURA R, Yokoi A, Matsumoto T, Oguri Y, et al
    Nodal induces apoptosis and inhibits proliferation in ovarian endometriosis-clear cell carcinoma lesions.
    BMC Cancer. 2019;19:308.
    PubMed     Abstract available

  90. GORNJEC A, Novakovic S, Stegel V, Hocevar M, et al
    Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
    BMC Cancer. 2019;19:296.
    PubMed     Abstract available

    March 2019
  91. ABDULRASHID K, AlHussaini N, Ahmed W, Thalib L, et al
    Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.
    BMC Cancer. 2019;19:256.
    PubMed     Abstract available

  92. GAO C, Yao H, Liu H, Feng Y, et al
    TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
    BMC Cancer. 2019;19:237.
    PubMed     Abstract available

  93. YE S, Liu S, Xiang L, Wu X, et al
    (18)F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications.
    BMC Cancer. 2019;19:226.
    PubMed     Abstract available

  94. LI C, Zhang Q, Zhang S, Dong R, et al
    Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review.
    BMC Cancer. 2019;19:217.
    PubMed     Abstract available

    February 2019
  95. CHEN X, Li X, Wang X, Zhu Q, et al
    MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research.
    BMC Cancer. 2019;19:171.
    PubMed     Abstract available

  96. LAN C, Li J, Huang X, Heindl A, et al
    Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer.
    BMC Cancer. 2019;19:159.
    PubMed     Abstract available

  97. ABU-SHAWER O, Abu-Shawer M, Hirmas N, Alhouri A, et al
    Hematologic markers of distant metastases and poor prognosis in gynecological cancers.
    BMC Cancer. 2019;19:141.
    PubMed     Abstract available

    January 2019
  98. NIEUWENHUYZEN-DE BOER GM, Hofhuis W, Reesink-Peters N, Ewing-Graham PC, et al
    Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
    BMC Cancer. 2019;19:58.
    PubMed     Abstract available

  99. BALOCH T, Lopez-Ozuna VM, Wang Q, Matanis E, et al
    Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    BMC Cancer. 2019;19:44.
    PubMed     Abstract available

  100. COTRIM DP, Ribeiro ARG, Paixao D, de Queiroz Soares DC, et al
    Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    BMC Cancer. 2019;19:4.
    PubMed     Abstract available

    December 2018
  101. MCGUIRE WP, Penson RT, Gore M, Herraez AC, et al
    Randomized phase II study of the PDGFRalpha antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    BMC Cancer. 2018;18:1292.
    PubMed     Abstract available

  102. CONTEDUCA V, Gurioli G, Rossi L, Scarpi E, et al
    Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
    BMC Cancer. 2018;18:1267.
    PubMed     Abstract available

  103. BAI Y, Li LD, Li J, Lu X, et al
    Prognostic values of S100 family members in ovarian cancer patients.
    BMC Cancer. 2018;18:1256.
    PubMed     Abstract available

  104. AKHAVAN S, Ghahghaei-Nezamabadi A, Modaresgilani M, Mousavi AS, et al
    Impact of diabetes mellitus on epithelial ovarian cancer survival.
    BMC Cancer. 2018;18:1246.
    PubMed     Abstract available

  105. KIM S, Lee M, Dhanasekaran DN, Song YS, et al
    Activation of LXRa/beta by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.
    BMC Cancer. 2018;18:1232.
    PubMed     Abstract available

  106. OGISHIMA J, Taguchi A, Kawata A, Kawana K, et al
    The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.
    BMC Cancer. 2018;18:1201.
    PubMed     Abstract available

    November 2018
  107. RODRIGUEZ-VELAZQUEZ A, Velez R, Lafontaine JC, Colon-Echevarria CB, et al
    Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
    BMC Cancer. 2018;18:1177.
    PubMed     Abstract available

  108. LEE IO, Lee JY, Kim HJ, Nam EJ, et al
    Prognostic significance of supradiaphragmatic lymph node metastasis detected by (18)F-FDG PET/CT in advanced epithelial ovarian cancer.
    BMC Cancer. 2018;18:1165.
    PubMed     Abstract available

  109. JIA SZ, Zhang JJ, Liang ZY, Yang JJ, et al
    Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours.
    BMC Cancer. 2018;18:1160.
    PubMed     Abstract available

  110. FANG C, Zhao L, Chen X, Yu A, et al
    The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (</=40 years old) with borderline ovarian tumors.
    BMC Cancer. 2018;18:1147.
    PubMed     Abstract available

  111. YOSHIMURA A, Sawada K, Nakamura K, Kinose Y, et al
    Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
    BMC Cancer. 2018;18:1065.
    PubMed     Abstract available

    October 2018
  112. ARORA N, Talhouk A, McAlpine JN, Law MR, et al
    Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada.
    BMC Cancer. 2018;18:1039.
    PubMed     Abstract available

  113. GAO T, Yu Y, Cong Q, Wang Y, et al
    Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.
    BMC Cancer. 2018;18:999.
    PubMed     Abstract available

  114. SCHULER-TOPRAK S, Weber F, Skrzypczak M, Ortmann O, et al
    Estrogen receptor beta is associated with expression of cancer associated genes and survival in ovarian cancer.
    BMC Cancer. 2018;18:981.
    PubMed     Abstract available

  115. SUZUKI Y, Tokinaga-Uchiyama A, Mizushima T, Maruyama Y, et al
    Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment.
    BMC Cancer. 2018;18:973.
    PubMed     Abstract available

  116. BRUNETTE LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, et al
    Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    BMC Cancer. 2018;18:970.
    PubMed     Abstract available

  117. MCGRATH SE, Annels N, Madhuri TK, Tailor A, et al
    Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.
    BMC Cancer. 2018;18:943.
    PubMed     Abstract available

    September 2018
  118. KISELEV VI, Ashrafyan LA, Muyzhnek EL, Gerfanova EV, et al
    A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.
    BMC Cancer. 2018;18:904.
    PubMed     Abstract available

  119. FENG Z, Wen H, Ju X, Bi R, et al
    The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer.
    BMC Cancer. 2018;18:883.
    PubMed     Abstract available

    August 2018
  120. LIM MC, Won YJ, Lim J, Salehi T, et al
    Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study.
    BMC Cancer. 2018;18:800.
    PubMed     Abstract available

    July 2018
  121. SHOJI T, Komiyama S, Kigawa J, Tanabe H, et al
    An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevaci
    BMC Cancer. 2018;18:771.
    PubMed     Abstract available

  122. URPILAINEN E, Marttila M, Hautakoski A, Arffman M, et al
    Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study.
    BMC Cancer. 2018;18:767.
    PubMed     Abstract available

    June 2018
  123. YOUNG EL, Thompson BA, Neklason DW, Firpo MA, et al
    Pancreatic cancer as a sentinel for hereditary cancer predisposition.
    BMC Cancer. 2018;18:697.
    PubMed     Abstract available

  124. PAJARES B, Porta J, Porta JM, Sousa CF, et al
    Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
    BMC Cancer. 2018;18:647.
    PubMed     Abstract available

  125. XINTAROPOULOU C, Ward C, Wise A, Queckborner S, et al
    Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.
    BMC Cancer. 2018;18:636.
    PubMed     Abstract available

    May 2018
  126. LEE JY, Kim S, Kim YT, Lim MC, et al
    Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.
    BMC Cancer. 2018;18:601.
    PubMed     Abstract available

  127. SANCHEZ VEGA JF, Murillo Bacilio MDR, Vintimilla Condoy AS, Palta Gonzalez AM, et al
    Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker.
    BMC Cancer. 2018;18:587.
    PubMed     Abstract available

    April 2018
  128. BAUERSFELD SP, Kessler CS, Wischnewsky M, Jaensch A, et al
    The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
    BMC Cancer. 2018;18:476.
    PubMed     Abstract available

  129. SEEBACHER V, Polterauer S, Reinthaller A, Koelbl H, et al
    AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer - a retrospective multi-centre study.
    BMC Cancer. 2018;18:447.
    PubMed     Abstract available

  130. ZHU Y, Zhou S, Liu Y, Zhai L, et al
    Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review.
    BMC Cancer. 2018;18:443.
    PubMed     Abstract available

  131. TANG Z, Yang J, Wang X, Zeng M, et al
    Active DNA end processing in micronuclei of ovarian cancer cells.
    BMC Cancer. 2018;18:426.
    PubMed     Abstract available

  132. RAMSER M, Eichelberger S, Daster S, Weixler B, et al
    High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.
    BMC Cancer. 2018;18:425.
    PubMed     Abstract available

    March 2018
  133. LE PAGE C, Rahimi K, Kobel M, Tonin PN, et al
    Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    BMC Cancer. 2018;18:347.
    PubMed     Abstract available

  134. ZHAO D, Wang X, Zhang W
    GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
    BMC Cancer. 2018;18:328.
    PubMed     Abstract available

  135. DE LEO A, Nannini M, Dondi G, Santini D, et al
    Unusual bilateral ovarian metastases from ileal gastrointestinal stromal tumor (GIST): a case report.
    BMC Cancer. 2018;18:301.
    PubMed     Abstract available

  136. HANLEY GE, McAlpine JN, Miller D, Huntsman D, et al
    A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    BMC Cancer. 2018;18:254.
    PubMed     Abstract available

    February 2018
  137. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Abstract available

  138. BRACKMANN M, Stasenko M, Uppal S, Erba J, et al
    Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
    BMC Cancer. 2018;18:172.
    PubMed     Abstract available

  139. MANDATO VD, Torricelli F, Mastrofilippo V, Valli R, et al
    Primary extra-uterine and extra-ovarian mullerian adenosarcoma: case report and literature review.
    BMC Cancer. 2018;18:134.
    PubMed     Abstract available

    January 2018
  140. O'DONNELL T, Christie EL, Ahuja A, Buros J, et al
    Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
    BMC Cancer. 2018;18:87.
    PubMed     Abstract available

  141. GUO Y, Zeng H, Chang X, Wang C, et al
    Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models.
    BMC Cancer. 2018;18:81.
    PubMed     Abstract available

  142. PARK JS, Lee ST, Nam EJ, Han JW, et al
    Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    BMC Cancer. 2018;18:83.
    PubMed     Abstract available

  143. WU N, Ren D, Li S, Ma W, et al
    RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
    BMC Cancer. 2018;18:67.
    PubMed     Abstract available

  144. HOLLIS RL, Meynert AM, Churchman M, Rye T, et al
    Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
    BMC Cancer. 2018;18:16.
    PubMed     Abstract available

    December 2017
  145. DU J, Shi HR, Ren F, Wang JL, et al
    Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    BMC Cancer. 2017;17:851.
    PubMed     Abstract available

  146. MIAO F, Zhang X, Cao Y, Wang Y, et al
    Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.
    BMC Cancer. 2017;17:838.
    PubMed     Abstract available

  147. SMITS S, Boivin J, Menon U, Brain K, et al
    Influences on anticipated time to ovarian cancer symptom presentation in women at increased risk compared to population risk of ovarian cancer.
    BMC Cancer. 2017;17:814.
    PubMed     Abstract available

    November 2017
  148. DA SILVA RF, Cardozo DM, Rodrigues GOL, Souza-Araujo CN, et al
    CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.
    BMC Cancer. 2017;17:756.
    PubMed     Abstract available

  149. KIECHLE M, Dukatz R, Yahiaoui-Doktor M, Berling A, et al
    Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1).
    BMC Cancer. 2017;17:752.
    PubMed     Abstract available

    October 2017
  150. ZHU M, Jia N, Huang F, Liu X, et al
    Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
    BMC Cancer. 2017;17:696.
    PubMed     Abstract available

    September 2017
  151. JAMES FR, Jiminez-Linan M, Alsop J, Mack M, et al
    Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.
    BMC Cancer. 2017;17:657.
    PubMed     Abstract available

  152. SMEBYE ML, Agostini A, Johannessen B, Thorsen J, et al
    Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
    BMC Cancer. 2017;17:642.
    PubMed     Abstract available

    August 2017
  153. CHAN KKL, Siu MKY, Jiang YX, Wang JJ, et al
    Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
    BMC Cancer. 2017;17:606.
    PubMed     Abstract available

  154. TONG JG, Valdes YR, Sivapragasam M, Barrett JW, et al
    Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.
    BMC Cancer. 2017;17:594.
    PubMed     Abstract available

  155. OHSUGA T, Yamaguchi K, Kido A, Murakami R, et al
    Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    BMC Cancer. 2017;17:580.
    PubMed     Abstract available

    July 2017
  156. MAATTA KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, et al
    Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    BMC Cancer. 2017;17:496.
    PubMed     Abstract available

  157. EOH KJ, Yoon JW, Lee JY, Nam EJ, et al
    A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
    BMC Cancer. 2017;17:481.
    PubMed     Abstract available

  158. SWIATLY A, Horala A, Hajduk J, Matysiak J, et al
    MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    BMC Cancer. 2017;17:472.
    PubMed     Abstract available

    June 2017
  159. GEORGE A, McLachlan J, Tunariu N, Della Pepa C, et al
    The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
    BMC Cancer. 2017;17:456.
    PubMed     Abstract available

  160. WANG S, Wei H, Zhang S
    Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion.
    BMC Cancer. 2017;17:455.
    PubMed     Abstract available

  161. YANG J, Zhou Y, Ng SK, Huang KC, et al
    Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    BMC Cancer. 2017;17:422.
    PubMed     Abstract available

    May 2017
  162. ZANOTTI L, Romani C, Tassone L, Todeschini P, et al
    MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
    BMC Cancer. 2017;17:366.
    PubMed     Abstract available

  163. SCHULER-TOPRAK S, Moehle C, Skrzypczak M, Ortmann O, et al
    Effect of estrogen receptor beta agonists on proliferation and gene expression of ovarian cancer cells.
    BMC Cancer. 2017;17:319.
    PubMed     Abstract available

  164. YE S, He T, Liang S, Chen X, et al
    Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma.
    BMC Cancer. 2017;17:317.
    PubMed     Abstract available

  165. LEVAN K, Mehryar M, Mateoiu C, Albertsson P, et al
    Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
    BMC Cancer. 2017;17:303.
    PubMed     Abstract available

    April 2017
  166. LIU Y, Chen S, Zheng C, Ding M, et al
    The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
    BMC Cancer. 2017;17:285.
    PubMed     Abstract available

    March 2017
  167. PETERS IT, van der Steen MA, Huisman BW, Hilders CG, et al
    Morphological and phenotypical features of ovarian metastases in breast cancer patients.
    BMC Cancer. 2017;17:206.
    PubMed     Abstract available

    February 2017
  168. TILBURY KB, Campbell KR, Eliceiri KW, Salih SM, et al
    Stromal alterations in ovarian cancers via wavelength dependent Second Harmonic Generation microscopy and optical scattering.
    BMC Cancer. 2017;17:102.
    PubMed     Abstract available

  169. GANSMO LB, Bjornslett M, Halle MK, Salvesen HB, et al
    MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
    BMC Cancer. 2017;17:97.
    PubMed     Abstract available

    January 2017
  170. MIYAMOTO S, Yotsumoto F, Ueda T, Fukami T, et al
    BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.
    BMC Cancer. 2017;17:89.
    PubMed     Abstract available

  171. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Abstract available

  172. AYYAGARI VN, Hsieh TJ, Diaz-Sylvester PL, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    BMC Cancer. 2017;17:49.
    PubMed     Abstract available

  173. BRANDT S, Samartzis EP, Zimmermann AK, Fink D, et al
    Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    BMC Cancer. 2017;17:44.
    PubMed     Abstract available

  174. TEMPFER CB, Hartmann F, Hilal Z, Rezniczek GA, et al
    Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report.
    BMC Cancer. 2017;17:26.
    PubMed     Abstract available

    December 2016
  175. MAISTRO S, Teixeira N, Encinas G, Katayama ML, et al
    Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    BMC Cancer. 2016;16:934.
    PubMed     Abstract available

    November 2016
  176. NAKAMURA H, Nagasaka K, Kawana K, Taguchi A, et al
    Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
    BMC Cancer. 2016;16:897.
    PubMed     Abstract available

  177. YU X, Zhang Y, Chen H
    LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    BMC Cancer. 2016;16:846.
    PubMed     Abstract available

  178. SHEN CC, Hu LY, Yang AC, Chiang YY, et al
    Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.
    BMC Cancer. 2016;16:839.
    PubMed     Abstract available

    October 2016
  179. YE H, Liu X, Sun J, Zhu S, et al
    Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer.
    BMC Cancer. 2016;16:831.
    PubMed     Abstract available

  180. ORNELAS A, McCullough CR, Lu Z, Zacharias NM, et al
    Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.
    BMC Cancer. 2016;16:824.
    PubMed     Abstract available

  181. HICKS DA, Galimanis CE, Webb PG, Spillman MA, et al
    Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration.
    BMC Cancer. 2016;16:788.
    PubMed     Abstract available

    February 2016
  182. NARENDRULA R, Mispel-Beyer K, Guo B, Parissenti AM, et al
    RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
    BMC Cancer. 2016;16:146.
    PubMed     Abstract available

    January 2016
  183. BLOK F, Roes EM, van Leenders GJ, van Beekhuizen HJ, et al
    The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    BMC Cancer. 2016;16:18.
    PubMed     Abstract available

  184. PARK B, Park S, Shin HR, Shin A, et al
    Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea.
    BMC Cancer. 2016;16:5.
    PubMed     Abstract available

  185. LI X, Shen B, Chen Q, Zhang X, et al
    Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
    BMC Cancer. 2016;16:251.
    PubMed     Abstract available

  186. CHANG YH, Li WH, Chang Y, Peng CW, et al
    Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
    BMC Cancer. 2016;16:235.
    PubMed     Abstract available

  187. DROESER RA, Mechera R, Daster S, Weixler B, et al
    MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
    BMC Cancer. 2016;16:639.
    PubMed     Abstract available

  188. NOTARO S, Reimer D, Fiegl H, Schmid G, et al
    Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
    BMC Cancer. 2016;16:589.
    PubMed     Abstract available

  189. WHICKER ME, Lin ZP, Hanna R, Sartorelli AC, et al
    MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    BMC Cancer. 2016;16:550.
    PubMed     Abstract available

  190. SMOGELI E, Davidson B, Cvancarova M, Holth A, et al
    L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
    BMC Cancer. 2016;16:596.
    PubMed     Abstract available

    January 2015
  191. MOTA A, Trivino JC, Rojo-Sebastian A, Martinez-Ramirez A, et al
    Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    BMC Cancer. 2015;15:940.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.